In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...
Giving patients with a common form of breast cancer an immunotherapy drug before surgery appears to boost outcomes, a n ...
Rosie Hawkins wanted to give son Jonathan, six, and daughter Freya, one, letters to remember her by right into old age ...
How an agreement set up by the Tories and lauded by Labour fell victim to cost-cutting and UK curbs on drugs expenditure ...
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
Investor's Business Daily on MSN18h
AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
In commemoration of World Cancer Day 2025, themed “United by Unique,” Betty Anyanwu-Akeredolu, widow of former Ondo State ...
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback